NCT06341660View on ClinicalTrials.gov

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 25, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

July 31, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

cadonilimab

Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.

Trial Locations (1)

510000

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangdong

All Listed Sponsors

lead

Guangzhou Institute of Respiratory Disease

OTHER